Integrated viral clearance strategies-reflecting on the present, projecting to the future
- PMID: 29367164
- DOI: 10.1016/j.copbio.2018.01.003
Integrated viral clearance strategies-reflecting on the present, projecting to the future
Abstract
Viral clearance and inactivation are critical steps in ensuring the safety of biological products derived from mammalian cell culture and are a component of an adventitious agent control strategy which spans both upstream and downstream processes. Although these approaches have been sufficient to support the development of biologics to date, the empirical and semi-quantitative nature of the approach leaves some potential gaps. For example, the concept of performing a quantitative risk assessment for the downstream components of virus safety was introduced in ICH Q5A for XMuLV. An ideal future state would be to perform a similar quantitative risk assessment for a range of viruses based on an assessment of potential virus risk in both upstream and downstream processes. This assessment combined with an integrated control strategy (including monitoring) would be extremely beneficial in minimizing potential adventitious agent risks. Significant progress has been achieved towards this goal in the last several years including recent advances in quantification of virus sequences in cell banks (ADVTIG), development of truly modular or generic viral clearance claims for specific unit operations, enhanced controls of upstream media (HTST/nanofiltration) and the use of RVLP for in-process monitoring. The recent shift towards continuous processing has the potential to enhance the criticality of in-line monitoring and the complexity of viral clearance and inactivation (owing to a wide range of potential 'worst case' viral clearance scenarios). However, gaps exist in, firstly, the ability to quantify potential virus risk levels in process streams in real-time, secondly, mechanistic understanding of virus/chromatography media interactions, and thirdly, mechanistic understanding of virus/filter interactions. Some new technologies may also need to be developed to allow for real-time confirmation of virus inactivation and clearance to support process development (both batch and continuous) and assessment of the impact of process deviations during manufacturing. This review paper provides an overview of the current state of an overall integrated control strategy for upstream and downstream processing and highlights the investments that could be pursued to achieve the future state of a quantitative virus risk assessment for a range of viruses. One potential approach to address these gaps is the use of data mining from large, comprehensive and diverse data sets to establish heuristic rules for virus detection, clearance and inactivation followed by specific hypothesis-driven experiments for cases that fall outside of the normal paradigm. Once this approach reaches a mature state suitable for implementation, there is an opportunity to update regulatory guidance (e.g. ICH Q5A) accordingly.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Adapting viral safety assurance strategies to continuous processing of biological products.Biotechnol Bioeng. 2017 Jan;114(1):21-32. doi: 10.1002/bit.26060. Epub 2016 Aug 17. Biotechnol Bioeng. 2017. PMID: 27474890 Review.
-
Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.Biotechnol Prog. 2015 Jan-Feb;31(1):135-44. doi: 10.1002/btpr.2020. Epub 2014 Nov 29. Biotechnol Prog. 2015. PMID: 25395156
-
Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):511-515. doi: 10.5731/pdajpst.2018.009175. Epub 2018 Jul 20. PDA J Pharm Sci Technol. 2018. PMID: 30030359
-
Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.PDA J Pharm Sci Technol. 2019 Mar-Apr;73(2):191-203. doi: 10.5731/pdajpst.2018.008862. Epub 2018 Oct 25. PDA J Pharm Sci Technol. 2019. PMID: 30361281
-
Suitability of a generic virus safety evaluation for monoclonal antibody investigational new drug applications.Biotechnol Prog. 2019 Sep;35(5):e2850. doi: 10.1002/btpr.2850. Epub 2019 Jun 9. Biotechnol Prog. 2019. PMID: 31125511 Review.
Cited by
-
Recombinant mucin biotechnology and engineering.Adv Drug Deliv Rev. 2023 Feb;193:114618. doi: 10.1016/j.addr.2022.114618. Epub 2022 Nov 11. Adv Drug Deliv Rev. 2023. PMID: 36375719 Free PMC article. Review.
-
Establishment of a keratinocyte and fibroblast bank for clinical applications in Japan.J Artif Organs. 2023 Mar;26(1):45-52. doi: 10.1007/s10047-022-01331-6. Epub 2022 May 5. J Artif Organs. 2023. PMID: 35511369
-
Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells.Cytotherapy. 2020 Aug;22(8):458-472. doi: 10.1016/j.jcyt.2020.04.099. Epub 2020 May 8. Cytotherapy. 2020. PMID: 32536505 Free PMC article.
-
Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.J Pharm Anal. 2020 Aug;10(4):291-312. doi: 10.1016/j.jpha.2020.01.002. Epub 2020 Jan 13. J Pharm Anal. 2020. PMID: 32292625 Free PMC article. Review.
-
Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation.Int J Nanomedicine. 2019 Nov 12;14:8847-8859. doi: 10.2147/IJN.S225453. eCollection 2019. Int J Nanomedicine. 2019. PMID: 32009783 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources